This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-effectiveness analysis
Study objective
The study examined the clinical and economic impact of four drug-eluting stents in diabetic patients who underwent a percutaneous coronary intervention (PCI). Analysis focused on an indirect comparison of the costs of sirolimus-eluting stents, paclitaxel-eluting stents, everolimus-eluting stents and zotarolimus-eluting stents (zotarolimus-eluting stents).
Interventions
The four drug-eluting stents under examination were sirolimus-(Cypher), paclitaxel-(Taxus), everolimus-(Xience) and zotarolimus-eluting (Endeavor) stents.
Location/setting
USA/hospital.
Methods

Analytical approach:
The analysis was based on a budget impact model with a one-year time horizon. The perspective of the health care payer was adopted.
Effectiveness data:
A review of the literature was undertaken to identify relevant clinical trials on the one-year target lesion revascularisation (TLR) risk, which was a key endpoint of the model. Retrieved studies were combined using an indirect comparison methodology that considered paclitaxel-eluting stents as the common comparator. Meta-analyses of each drug-eluting stent versus paclitaxel-eluting stents were completed using the random-effects model to provide relative risk ratios.
Twelve trials were found: all trials included paclitaxel-eluting stents, seven trials included sirolimus-eluting stents, two trials included zotarolimus-eluting stents and four included everolimus-eluting stents. The pooled population included 4,853 diabetic patients.
Monetary benefit and utility valuations:
Not considered.
Measure of benefit:
No summary benefit measure was used. Annual TLRs were the main endpoint of the analysis.
Cost data:
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The economic analysis included hospital costs associated with index PCI with drug-eluting stents, re-interventions, PCI with stent, PCI with drug-eluting stents, PCI with bare metal stents, PCI without stent and coronary artery bypass grafting (CABG). No cost differences were considered for the various drug-eluting stents. Prevalence of PCI was taken from a Canadian observational study. All costs were based on reimbursement rates for Medicare Severity Adjusted Diagnosis Related Groups. Costs were in USA dollars ($).
Analysis of uncertainty:
Two different methodologies were used for estimating TLR risk. In method one the exact point estimate relative risk (regardless of statistical significance) was multiplied by the weighted average TLR risk for paclitaxel-eluting stents. Method two multiplied a relative risk of 1.0 if meta-analyses showed non-significant results.
In one-way sensitivity analyses, the upper and lower relative risk confidence intervals for drug-eluting stents were multiplied by the weighted average TLR risk for paclitaxel-eluting stents. Another sensitivity analysis considered only studies that measured clinically-driven TLR when calculating the baseline weighted average TLR risk for paclitaxeleluting stents.
Results
The one-year TLR was 3.2% with sirolimus-eluting stents, 6.9% with paclitaxel-eluting stents, 7.1% with zotarolimuseluting stents and 7.9% with everolimus-eluting stents.
Using method one (different TLR risk for each drug-eluting stents) in a hypothetical cohort of 200,000 patients, predicted annual TLRs were 6,376 with sirolimus-eluting stents, 14,278 with zotarolimus-eluting stents, 13,862 with paclitaxel-eluting stents and 15,940 with everolimus-eluting stents. The corresponding population budget impact and per patient budget impact for the four drug-eluting stents were $3.62 billion and $18,125 with sirolimus-eluting stents, $3.78 billion and $18,899 with zotarolimus-eluting stents, $3.77 billion and $18,858 with paclitaxel-eluting stents and $3.81 billion and $19,060 with everolimus-eluting stents.
Sirolimus-eluting stents resulted in lower risk of TLR and were less costly than the other options. Sirolimus-eluting stents were the preferred intervention even when conservative assumptions were made (method two). This conclusion was further confirmed in the sensitivity analyses.
